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Introduction: Rheumatoid arthritis is an autoimmune disease that causes systemic involve-
ment and is associated with increased risk of cardiovascular disease.
Objective: To analyze the prediction index of 10-year risk of a fatal cardiovascular disease
event in female RA patients versus controls.
Methods: Case–control study with analysis of 100 female patients matched for age and gen-
der  versus 100 patients in the control group. For the prediction of 10-year risk of a fatal
cardiovascular disease event, the SCORE and modiﬁed SCORE (mSCORE) risk indexes were
used,  as suggested by EULAR, in the subgroup with two or more of the following: duration
of  disease ≥10 years, RF and/or anti-CCP positivity, and extra-articular manifestations.
Results: The prevalence of analyzed comorbidities was similar in RA patients compared with
the control group (p > 0.05). The means of the SCORE risk index in RA patients and in the
control group were 1.99 (SD: 1.89) and 1.56 (SD: 1.87) (p = 0.06), respectively. The means
of  mSCORE index in RA patients and in the control group were 2.84 (SD = 2.86) and 1.56
(SD  = 1.87) (p = 0.001), respectively. By using the SCORE risk index, 11% of RA patients were
classiﬁed as of high risk, and with the use of mSCORE risk index, 36% were at high risk
(p  < 0.001).
Conclusion: The SCORE risk index is similar in both groups, but with the application of the
mSCORE index, we recognized that RA patients have a higher 10-year risk of a fatal cardio-
vascular disease event, and this reinforces the importance of factors inherent to the diseasenot  measured in the SCORE risk index, but considered in mSCORE risk index.
© 2015 Elsevier Editora Ltda. All rights reserved.
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E-mail: ivanioreumato@gmail.com (I.A. Pereira).
http://dx.doi.org/10.1016/j.rbre.2015.09.005
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Avaliac¸ão  do  risco  cardiovascular  de  pacientes  com  artrite  reumatoide
utilizando  o  índice  SCORE
Palavras-chave:
Artrite reumatoide
Eventos vasculares
Risco cardiovascular
Fatores de risco
r  e  s  u  m  o
Introduc¸ão: Artrite Reumatóide (AR) é uma doenc¸a autoimune que determina manifestac¸ões
sistêmicas e está associada a aumento do risco de evento cardiovascular.
Objetivo: Objetiva-se neste estudo analisar o índice de predic¸ão de evento cardiovascular
em  pacientes do gênero feminino portadores de AR comparados a controles sem a doenc¸a.
Métodos: Estudo de caso-controle com análise de 100 pacientes pareadas por gênero e idade
versus 100 pacientes do grupo controle. Para a predic¸ão do risco de evento cardiovascular
fatal em 10 anos, utilizamos os índices SCORE e SCORE modiﬁcado (mSCORE), conforme
sugerido pela EULAR, no subgrupo com 2 ou mais dos seguintes: durac¸ão da doenc¸a ≥10
anos, positividade para fator reumatoide e/ou anti-CCP, e manifestac¸ões extra-articulares.
Resultados: A prevalência das comorbidades analisadas foi similar nas pacientes com AR,
em  comparac¸ão com o grupo controle (p > 0,05). As médias do índice SCORE foram 1,99 (DP:
1,89) e 1,56 (DP: 1,87) nas portadoras de AR e nos controles (p = 0,06), respectivamente. Com a
utilizac¸ão  do índice mSCORE, nas pacientes com AR foi encontrada a média de 2,84 (DP: 2,86)
versus 1,56 nos controles (DP: 1,87) (p = 0,001). Ao utilizar o índice SCORE, 11% dos portadores
de AR foram classiﬁcados como de alto risco; com o índice mSCORE, 36% obtiveram essa
classiﬁcac¸ão (p < 0,001).
Conclusões: O índice SCORE é semelhante nos dois grupos, mas com a aplicac¸ão do índice
mSCORE, identiﬁcamos que os pacientes com AR têm maior risco de evento cardiovascular
fatal em 10 anos, com ênfase na importância dos fatores inerentes à doenc¸a não mensurados
no  índice SCORE, mas considerados no índice mSCORE.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
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heumatoid arthritis (RA) is a systemic autoimmune disease
f unknown cause characterized mainly by the presence of
ynovial inﬂammation, cartilage damage and articular defor-
ity. This disease also determines systemic manifestations
nd is associated with multiple comorbidities.1
Studies have shown that the prevalence of RA is about
.5–1% of the population,2,3 and cardiovascular disease is the
eading cause of mortality in these patients. In a recently
ublished meta-analysis, the authors found that the risk of
ortality from cardiovascular disease (ischemic heart dis-
ase and stroke) is 50% higher in RA patients compared
o the general population.4 However, it is clear that early
therosclerosis observed in this group of patients cannot
e explained only by traditional cardiovascular risk fac-
ors. The formation of atherosclerotic plaques by a chronic
nﬂammatory disease process can come directly (acting on
he formation and destabilization of plaque) or indirectly
hrough aortic stiffening, which can lead to left ventricular
ypertrophy.5,6
In the general population, a number of cardiovascular risk
redictive scores has been used, such as the Framingham
core and the Systematic Coronary Risk Evaluation index
SCORE), in an attempt to predict risk and acting preventively
o avoid unfavorable outcomes. In RA patients, studies on the
se of these scores are scarce. According to the recommenda-
ions of the European League Against Rheumatism (EULAR),
CORE and modiﬁed SCORE (mSCORE) risk indexes should be
sed for risk prediction in this speciﬁc population.This study aimed to analyze the cardiovascular risk pre-
diction index according to SCORE and mSCORE indexes in RA
patients compared to controls without the disease.
Methods
This case–control study was conducted at the Movimento
Clinic, a center specialized in rheumatic diseases, at the Ref-
erence Polyclinic of UNSUL, and at the Primary Health Care
Group (ABS), located in the city of Palhoc¸a  (SC).
Medical records of female patients aged between 35 and 70
years old, diagnosed with RA and who met the 1987 disease
classiﬁcation criteria7 were analyzed. The control subjects
were matched for gender and age, and were not healthy
people; all members of this group suffered other diseases
(except RA), and were referred from an internal medicine
clinic, and theoretically were about equally likely exposed
to comorbidities and cardiovascular risk factors. The pres-
ence of diseases able to increase cardiovascular risk and/or
the use of medications which can intervene in assessed vari-
ables, were investigated (e.g., antihypertensive, hypoglycemic,
hypolipidemic agents). The inclusion of RA patients and of
control group subjects followed the criteria for a simple bicau-
dal random probability sample. Data collection observed a
strict standardization for the correct evaluation of the pres-the responsibility of the same single researcher. The sample
size calculation was performed using OpenEpi (Open Source
Epidemiologic Statistics for Public Health, Version 2.3.1)
 o l . 2140  r e v b r a s r e u m a t
program, with the following parameters: 95% conﬁdence inter-
val (CI 95%); power of 80%; control/case ratio 1:1; rate of
exposed controls: 20%; rate of exposed cases: 40%, totaling 100
cases and 100 controls.
Subjects meeting the following criteria8–10 were considered
as comorbidity carriers:
1. High blood pressure (BP): SBP ≥ 140 mm Hg; DBP ≥ 90 mm
Hg, or use of antihypertensive medication. Subjects with at
least three of these measurements on two different occa-
sions were considered as with hypertension (according to
VI Brazilian Guidelines on Hypertension, 2010).
2. Dyslipidemia: LDL cholesterol ≥ 130 mg/dL; Total choles-
terol ≥ 200 mg/dL; Triglycerides ≥ 150 mg/dL; HDL ≤
40 mg/dL; or use of statins (according to the classiﬁ-
cation of the Third Report of the National Cholesterol
Education Program [NCEP] Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults [Adult Treatment Panel III] Final Report).
3. Diabetes mellitus (DM): fasting glucose ≥ 126 mg/dL in two
samples; glycaemia ≥ 200 mg/dL in a 2-h tolerance test
(75 g of glucose); random blood glucose levels ≥ 200 mg/dL;
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Fig. 1 – SCORE risk index.
Source: European Guidelines on CVD Prevention in Clinical Practi
© European Society of Cardiology – doi:10.1093/eurheartj/EHS092 0 1 6;5 6(2):138–144
glycated hemoglobin ≥ 6.5% in 2 samples; use of hypo-
glycemic agents or insulin therapy (according to Standards
of Medical Care in Diabetes – 2011).
4. Smoking.
For cardiovascular risk prediction, we  used the high-risk
SCORE index (Fig. 1) which classiﬁes patients according to age,
gender, total cholesterol level, systolic blood pressure (SBP)
and tobacco use, using low-and high-risk matrices.11 Cross-
checking of data for each patient provides a cell containing a
number representing the numerical value of the SCORE risk
index, and a color representing the rate of 10-year risk of a
fatal cardiovascular disease event, to which each patient is
exposed.
To calculate the mSCORE risk index, the value initially col-
lected from the SCORE risk index was multiplied by a factor of
1.5 for RA patients that met  two out of the following three crite-
ria: a disease lasting more  than 10 years, RF and/or anti-CCP
positivity, and ﬁnally, patients with extra-articular manifesta-
tions.
Based on calculations of SCORE and mSCORE indexes,
patients who were classiﬁed with a chance ≥5% of a 10-year
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Table 1 – Comorbidities in RA patients (cases) and controls.
Variables Case Control Total p-Value OR (95% CI)
n(%) n(%) n(%)
Hypertension 0.32
Hypertensive 48 (48.0) 55 (55.0) 103 (51.5) 0.75 (0.43–1.31)
Not hypertensive 52 (52.0) 45 (45.0) 97 (48.5) 1
Dyslipidemia 0.29
Dyslipidemic 69 (69.0) 62 (62.0) 131 (65.5) 1.36 (0.76–2.45)
Not dyslipidemic 31 (31.0) 38 (38.0) 69 (34.5) 1
Diabetes mellitus 0.08
Diabetic 8 (8.0) 16 (16.0) 24 (12.0) 0.45 (0.18–1.12)
Nondiabetic 92 (92.0) 84 (84.0) 176 (88.0) 1
Heart failure 1
Yes 2 (2.0) 2 (2.0) 4 (2.0) 1.00 (0.13–7.24)
No 98 (98.0) 98 (98.0) 196 (98.0) 1
Coronary artery disease 0.09
Yes 5 (5.0) 1 (1.0) 6 (3.0) 5.21  (0.59–45.4)
No 95 (95.0) 99 (99.0) 194 (97.0) 1
Smoking 0.59
Yes 18 (18.0) 21 (21.0) 39 (19.5) 0.82 (0.41–1.66)
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event in both groups. At ﬁrst, we identiﬁed several comorbidi-
ties often present in studied groups and that deﬁnitely are
related to a worse cardiovascular prognosis.
Table 2 – Means of SCORE and mSCORE risk indexes in
cases and controls.
Variables RA p-Value
Case Control
Mean (SD) Mean (SD)
SCORE risk index 1.99 (1.89) 1.56 (1.87) 0.062
mSCORE risk index 2.84 (2.86) 1.56 (1.87) 0.001No 82 (82.0) 79 (79.0) 
isk of a fatal cardiovascular disease event were stratiﬁed as
f “high risk”.
The database was developed in Excel and exported to SPSS
6.0 program. Statistical analysis involved the evaluation of
ormality of quantitative variables. To verify the presence
f an association between independent variables and the
ependent variable, the Pearson chi-squared test for qualita-
ive variables and the Student’s t test for quantitative variables
ere used. OR association measure was used with the respec-
ive 95% CIs.
The study was submitted to Research Ethics Committee-
NISUL, having received approval for its realization.
esults
ata of 100 medical records of RA patients were included to
ompose the case group; and data of 100 medical records of
atients without a diagnosis of RA were included to make up
he control group. All study participants were female.
The mean age of RA group was 55.4 ± 8.9 years. In the con-
rol group, the mean age was 52.3 ± 7 years. The mean duration
f disease in RA patients was 14 ± 8 years. Among RA patients,
7% had a diagnosis of RA for more  than 10 years. 26% of
atients had an extra-articular manifestation (in most cases,
ulmonary involvement). Table 1 lists the analysis that deter-
ined the association between comorbidities of the study
articipants. There were no differences in the frequency of
omorbidities for both RA and control groups.
Table 2 reports the differences between SCORE and
SCORE risk index means. By analyzing the SCORE risk index
or 10-year risk of a fatal cardiovascular disease event for all
articipants studied, the following means were obtained: 1.99
SD: 1.89) for RA group and 1.56 (SD: 1.87) for the control group
p = 0.06). Using the mSCORE risk index, the following means
ere obtained: 2.84 (SD = 2.86) in RA group and 1.56 (SD 1.87) in161 (80.5) 1
the control group, with statistical signiﬁcance for this variable
(p = 0.001).
Table 3 lists the risk stratiﬁcation associating SCORE and
mSCORE indexes. The stratiﬁcation of patients studied into
subgroups with high- and low-risk for a 10-year risk of a fatal
cardiovascular disease event was based on the SCORE risk
index. This stratiﬁcation showed that 11% of RA patients and
7% of control group subjects were classiﬁed as of high-risk
(p = 0.32). When using the mSCORE for risk stratiﬁcation, it was
observed that 36% of RA patients and 7% in the control group
were classiﬁed as of high-risk (p < 0.001).
Discussion
In this study, a comparative analysis of patients with and with-
out RA was developed in order to establish SCORE and mSCORE
risk indexes for 10-year risk of a fatal cardiovascular diseaseRA, rheumatoid arthritis; SCORE, Systematic Coronary Risk Evalu-
ation; mSCORE, modiﬁed Systematic Coronary Risk Evaluation.
Source: Elaboration from the author (2012).
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Table 3 – Stratiﬁcation of risk associated to SCORE and mSCORE risk indexes.
Variables RA Total p-Value OR (95% CI)
Case Control n(%)
n(%) n(%)
SCORE risk index 0.323
Low risk 89 (89.0) 93 (93.0) 182 (91.0) 1
High risk 11 (11.0) 7 (7.0) 18 (9.0) 1.64 (0.61–4.42)
mSCORE risk index <0.001
Low risk 64 (64.0) 93 (93.0) 157 (78.5) 1
High risk 36 (36.0) 7 (7.0) 43 (21.5) 7.47 (3.13–17.84)
n; mRA, rheumatoid arthritis; SCORE, Systematic Coronary Risk Evaluatio
By analyzing the presence of hypertension in the study
subjects, the results showed similar rates of this comorbid-
ity in both groups. In a meta-analysis by Boyer et al.,12 with 15
case–control studies selected with 2956 cases and 2713 con-
trols from 1950 to 2008, no difference was observed in the
presence of hypertension in both groups. Although there are
inherent factors which contribute to the increase of blood
pressure, for example, a lower endothelium-derived nitric
oxide expression, higher endothelin and angiotensin II pro-
duction, and use of certain medications (e.g., leﬂunomide,
nonsteroidal anti-inﬂammatory drugs and corticosteroids),
these factors per se are not enough to determine a difference in
prevalence of hypertension among RA patients versus controls
without the disease.
Dyslipidemia was a common ﬁnding, but this ﬁnding
was not more  frequent than in the control group. Moreover,
Urowitz13 found slightly higher levels of total cholesterol in
patients diagnosed with RA when compared to patients with-
out the disease. One of the features of the lipid proﬁle of these
patients was also observed, that is, blood levels of HDL were
lower than in the general population. Toms et al.14 mention
that such comorbidity affects 55–65% of RA patients, both in
early-stage and late-stage disease. Turning their attention to
blood levels of HDL in the groups studied, these authors found
lower levels of HDL in RA population. In this same study,
the authors mention that, in addition to genetic predisposi-
tion (which may be a potential cause of dyslipidemia in these
patients), other factors would be acting, such as inﬂammatory
disease activity, physical inactivity due to illness, and use of
certain medications.
In comparison with the general population, patients diag-
nosed with RA are at a twofold increased risk to suffer a
cardiovascular event; and the magnitude of this increase is
comparable to the risk of cardiovascular events in patients
with type 2 diabetes mellitus.15 Such ﬁgures reinforce the
importance of identifying RA patients diagnosed with under-
lying DM,  for this knowledge can avoid unfavorable outcomes.
In this study, in comparison with RA group, the control
group showed a tendency for a twofold increased preva-
lence of DM,  but without statistical signiﬁcance. Changes
in blood glucose levels of RA patients can be explained
by modiﬁable factors such as abdominal obesity, use of
antihypertensive agents, disease activity, and the use of
corticosteroids.16 In a meta-analysis by Boyer et al.,12 the fre-
quency of DM in RA patients was higher than that in theSCORE, modiﬁed Systematic Coronary Risk Evaluation.
control group (p = 0.003); and other studies also found similar
ﬁndings.17,18
Another important comorbidity studied in this manuscript
was smoking, with a similar frequency in both case and
control groups. In a historical cohort study, Kremers et al.19
found a prevalence of 52% of smoking in RA patients (p = 0.004)
and of 43% in the group without the disease. Another meta-
analysis, which reinforces the higher frequency of smokers
in RA patients versus the general population, was con-
ducted by Boyer et al.,12 with OR = 1.56 (95% CI 1.35–1.80;
p < 0.00001). It is believed that the low frequency of smoking
in RA patients compared with historical cohorts is derived
from the more  detailed information received by patients
about the harmful effects of this habit; patients are aware
that this habit would result in lower response to treat-
ment, more  severe disease and increased cardiovascular
risk.
The tools designed to assess cardiovascular risk in the gen-
eral population, such as the Framingham score, cannot predict
the actual cardiovascular risk in RA patients, because, despite
the key role of inﬂammation in the development of atheroscle-
rosis, in clinical practice this factor is overlooked in many
risk stratiﬁcation tools. Crowson et al.,20 in a study of 525 RA
patients aged less than 30 years, analyzed Framingham and
Reynolds scores for assessment of cardiovascular risk. These
authors concluded that these scores substantially underesti-
mate cardiovascular risk in RA patients (both genders), mainly
in advanced age, in RF-positive subjects, and with persistently
high rates of ESR, which is an important marker of inﬂam-
matory activity of the disease. Such outcomes can result in
missed opportunities for preventive medical interventions,
and also create a false sense of security in medical practice
in the prediction of the actual cardiovascular risk to which
patients are subjected.
The SCORE project was established in 2003 by ESC (Euro-
pean Society of Cardiology) in collaboration with the Third
Joint Task Force in order to develop a risk assessment sys-
tem for clinical practice in Europe. To carry out this project,
data from cohort studies from 12 European countries, totaling
205,178 people, were used, representing 2.7 million person-
years of follow-up. The 10-year risk of a fatal cardiovascular
disease event was calculated, and “age” was used as a measure
of risk exposure time, instead of being considered as a risk fac-
tor; such calculations were made for high- and low-risk areas
for cardiovascular events.
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Then, the group developed a simple matrix for risk calcu-
ation, providing a direct estimate of 10-year risk of a fatal
ardiovascular disease event in a format suitable for the limi-
ations of clinical practice.21
In a study by Peters et al.11 that aimed to develop evidence-
ased recommendations from the European League Against
heumatism (EULAR) in RA, ankylosing spondylitis and pso-
iatic arthritis patients, the orientation of the authors was
hat in countries in which there was no evaluation guidelines
or cardiovascular risk in these populations, the SCORE risk
ndex should be used. In another study conducted by Rosales
lexander et al.,22 the authors observed a signiﬁcant associ-
tion among the SCORE risk index and CRP levels (p < 0.034),
he presence of extra-articular manifestations (p < 0.048), more
han 10 years of disease duration (p < 0.001), suggesting a
elationship of cardiovascular risk and RA severity with cumu-
ative duration of inﬂammation maintained over the years.
hese data provided information that allowed the EULAR com-
ittee of experts make an adjustment of calculations for the
CORE risk index for patients with at least two out of three
f the following factors (a disease with >10 years, RF and/or
nti-CCP positivity, and presence of extra-articular manifes-
ations), with the use of a multiplying factor of 1.5 to obtain
he modiﬁed SCORE risk index (mSCORE).11
In our study, it is worthwhile to note that RA patients
emonstrated a greater tendency for obtaining a higher pre-
iction of 10-year risk of a fatal cardiovascular disease event
hen using the classical SCORE matrix, and that the signif-
cance of this difference was established with the use of the
odiﬁed SCORE risk index, with the application of a multiply-
ng factor of 1.5 to the subgroup. This risk difference, found
n RA patients, is in accordance with the higher prevalence
f cardiovascular events and of mortality from this cause, a
act already conﬁrmed in several epidemiological studies pre-
iously conducted.
The study by Gómez-Vaquero et al.,23 with 200 RA patients,
imed to assess the impact of EULAR recommendations on
he cardiovascular risk approach. Its authors found that 11%
f patients to whom the classical SCORE risk index was applied
nd 14% of those assessed with the mSCORE were classiﬁed
s of high-risk (≥5%) for 10-year risk of a fatal cardiovascular
isease event.
Data such as these emphasize the need to incorporate
hose factors inherent to the disease to cardiovascular risk
tratiﬁcation tools in RA patients; these factors per se increase
he cardiovascular mortality rates.
We can conclude that, according to the EULAR recommen-
ations, the application of the modiﬁed SCORE matrix in RA
atients allows us to recognize, in this population at risk, a
ubgroup of patients with a higher 10-year risk of a fatal car-
iovascular disease event in need of an early and intensive
harmacological intervention and of the use of therapeutic
argets to determine a lower risk of future cardiovascular
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